Kodiak spikes as J.P. Morgan upgrades on eye disease drug, KSI-101

Kodiak Sciences (KOD) stock gains as J.P. Morgan upgrades, arguing that a recent trial readout from Roche (RHHBY) derisked the firm's eye drug KSI-101. Read more here.

[Ad hoc announcement pursuant to Art. 53 LR] Roche continues strong sales growth momentum of 7% (CER) in the first nine months of 2025; full-year earnings outlook raised

Basel, 23 October 2025 Group sales grew by 7%1 at constant exchange rates (CER; 2% in CHF) in the first nine months, driven by high demand for our innovative medicines and diagnostics.Pharmaceuticals ...
Edinburgh News

Edinburgh Royal Children’s Hospital to install meerkats experience enclosure after plans approved

Edinburgh Royal Children’s Hospital is set to install a new meerkats enclosure for patients to enjoy, after the plans were ...